© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
October 02, 2020
The agency approved the first and only immunotherapy treatment as a first-line therapy for adult patients with unresectable malignant pleural mesothelioma.
September 21, 2020
“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.
Treatment with a novel BiTE® immuno-oncology therapy showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.
September 20, 2020
The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.